Doha-based Weill Cornell Medicine-Qatar (WCM-Q) has said that it has signed a research agreement with US-based biotechnology company, Moderna, it was reported on Monday.
The two firms are to work together to develop a new drug for controlling cholesterol. The firms are hoping that the new drug would improve treatments for type 2 diabetes and cardiovascular disease.
The agreement would see Moderna sponsor a study by WCM-Q researcher, Dr Hani Najafi.
Since its launch in 2010, Moderna has developed a technology platform for developing mRNA-based therapies.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal